CBX4 Expression and AFB1-Related Liver Cancer Prognosis

Su, Qun-Ying; Lü, Jun; Huang, Xiaoying; Yao, Jin-Guang; Xue-MinWu,; Huang, Bing-Chen; Wang, Chao; Xia, Qiang; Long, Xi-Dai

doi:10.5772/intechopen.78580

Cited by 3 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is because AFB1-DNA adducts are usually characterized by non-enzyme, time-dependence, and apparent persistence and can result in the activation of oncogenes (such as Ras) and the inactivation of tumor suppressor genes (such as TP53) [20,21]. Furthermore, amount of AFB1-DNA adducts in liver tissues are proved to positively correlate with tumor MVD [10]. Here, our data also showed that HCC patients with increasing amount of AFB1-DNA adducts would feature a shorten OS and RFS and an increased death risk and tumor recurrence risk.…”

Section: Discussionmentioning

confidence: 99%

“…This may be because of rs77447679 SNP may regulate CBX4 expression and the dysregulation of CBX4 expression could promote tumor angiogenesis, increase tumor MVD, and affect tumor sensitivity on anti-cancer drugs [8,9]. An our recent study from high AFB1 exposure areas has displayed that increasing CBX4 protein expression in the tissues with HCC is significantly associated with poor survival of patients with AFB1-related HCC [10]. Taken together, these results suggest that CBX4 rs77447679 SNP may involve in the progression of HCC, especially cancer caused by AFB1 exposure.…”

Section: Discussionmentioning

confidence: 99%

“…Functionally, CBX4 mainly involves in PRC1regulated transcription repression and post-translation modification [6,7]. Our previous studies have also displayed that the dysregulation of CBX4 progress hepatocarcinoma angiogenesis and affects the prognosis of patients with HCC [8][9][10]. Recently, several reports have been indicative of genetic variants in this gene [11,12].…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

The predictive potential of genetic single nucleotide polymorphisms in CBX4 for hepatocellular carcinoma survival

Zhu

Huang

et al. 2021

Front Biosci (Landmark Ed)

View full text Add to dashboard Cite

Introduction 3. Materials and methods 3.1 Study design and subjects 3.2 AFB1 exposure data 3.3 SNPs selection and genotyping 3.4 Immunochemistry 3.5 Statistical analysis 4. Results 4.1 The demographic and clinicopathological features and the survival of HCC patients 4.2 Univariable analyses indicating CBX4 SNPs as significant prognostic biomarker for HCCs' survival 4.3 The effects of CBX4 rs77447679 SNP on survival stratified by the clinicopathological features of HCC patients 4.4 Multivariable analyses indicating CBX4 rs77447679 SNP as an independent prognostic factor for patients with HCC 4.5 CBX4 rs77447679 but not rs2289728 SNP significantly linking with CBX4 protein expression 4.6 CBX4 rs77447679 SNP differently regulating the therapeutic effects of pa-TACE on HCC 5. Discussion 6. Conclusions 7. Author contributions 8. Ethics approval and consent to participate 9. Acknowledgment 10. Funding 11. Conflict of interest 12. References

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

The predictive potential of genetic single nucleotide polymorphisms in CBX4 for hepatocellular carcinoma survival

Zhu

Huang

et al. 2021

Front Biosci (Landmark Ed)

View full text Add to dashboard Cite

show abstract

“…Evidence from clinicopathological studies has displayed that there is an increasing heterogenic expression profile of chromobox 4 (CBX4) in tumor tissular samples with HADA and this alteration statistically modifies the therapeutic efficiency of po-TACE treatment on HCC [ 19 ]. This may be result from the upregulation of CBX4 expression accelerating tumor angiogenesis and next inducing tumor proliferation and decreasing cancerous cells’ sensibility on anticancer drugs [ 14 , 19 , 36 ]. The present study furthermore proved that the levels of ADAs in tumor tissues were linked with tumor MVD.…”

Section: Discussionmentioning

confidence: 99%

“…Molecular epidemiological studies conducted in high AFB1 exposure areas show that the genetic alterations in DNA repair genes (including XPC, XRCC4, XRCC1, and XPD) are not only associated with low DNA damage repair capacity and result in increasing amounts of ADAs, but also increase HCC risk and short survival of patients with HCC [15,[30][31][32][33]. For example, genetic alteration at the coding region of DNA repair gene XRCC4 increased the amount of ADAs in the HCC cells and change the sensibility of cancer cells on anticancer drug doxorubicin [34,35]. Third, ADAs maybe affect the process of tumor angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Aflatoxin B1-DNA adducts modify the effects of post-operative adjuvant transarterial chemoembolization improving hepatocellular carcinoma prognosis

Huang,

Long,

et al. 2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Aim: In renal cell carcinoma (RCC), tumor heterogeneity generated challenges to biomarker development and therapeutic management, often becoming responsible for primary and acquired drug resistance. This study aimed to assess the inter-tumoral, intra-tumoral, and intra-lesional heterogeneity of known druggable targets in metastatic RCC (mRCC). Methods: The RIVELATOR study was a monocenter retrospective analysis of biological samples from 25 cases of primary RCC and their paired pulmonary metastases. The biomarkers analyzed included MET, mTOR, PD-1/PD-L1 pathways and the immune context. Results: High multi-level heterogeneity was demonstrated. MET was the most reliable biomarker, with the lowest intratumor heterogeneity: the positive mutual correlation between MET expression in primary tumors and their metastases had a significantly proportional intensity (P = 0.038). The intratumor heterogeneity grade was significantly higher for the mTOR pathway proteins. Combined immunophenotypical expression patterns and their correlations with the immune context were uncovered [i.e., mTOR expression in the metastases positively correlated with PD-L1 expression in tumor-infiltrating lymphocytes (TILs), P = 0.019; MET expression was related to PD-1 expression on TILs (P = 0.041, ρ = 0.41) and peritumoral lymphocytes (RILs; P = 0.013, ρ = 0.49)], suggesting the possibility of predicting drug response or resistance to tyrosine kinase, mTOR, or immune checkpoint inhibitors. Conclusions: In mRCC, multiple and multi-level assays of potentially predictive biomarkers are needed for their reliable translation into clinical practice. The easy-to-use immunohistochemical method of the present study allowed the identification of different combined expression patterns, providing cues for planning the management of systemic treatment combinations and sequences in an mRCC patient population. The quantitative heterogeneity of the investigated biomarkers suggests that multiple intralesional assays are needed to consider the assessment reliable for clinical considerations.

show abstract

Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma

Liang,

Long,

Tian

et al. 2024

World J Hepatol

View full text Add to dashboard Cite

BACKGROUND The dysregulation of tissue inhibitor of metalloproteinase-3 (TIMP3) was positively correlated with the progression of hepatocellular carcinoma (HCC). However, it is not clear whether TIMP3 expression is associated with the clinicopathological features and prognosis of aflatoxin B1 (AFB1)-related HCC (AHCC). AIM To assess the effects of TIMP3 expression on the clinicopathological features and prognosis of AHCC. METHODS A retrospective study, including 182 patients with AHCC, was conducted to explore the link between TIMP3 expression in cancerous tissues and the clinicopathological characteristics and prognosis of AHCC. TIMP3 expression was detected by immunohistochemistry and its effects on the clinicopathological features and prognosis of AHCC were evaluated by Kaplan-Meier survival analysis and Cox regression survival analysis. Odds ratio, hazard ratio (HR), median overall survival time (MST), median tumor recurrence-free survival time (MRT), and corresponding 95% confidential interval (CI) was calculated to evaluate the potential of TIMP3 expression in predicting AHCC prognosis. RESULTS Kaplan-Meier survival analysis showed that compared with high TIMP3 expression, low TIMP3 expression in tumor tissues significantly decreased the MST (36.00 mo vs 18.00 mo) and MRT (32.00 mo vs 16 mo) of patients with AHCC. Multivariate Cox regression survival analysis further proved that decreased expression of TIMP3 increased the risk of death (HR = 2.85, 95%CI: 2.04-4.00) and tumor recurrence (HR = 2.26, 95%CI: 1.57-3.26). Furthermore, decreased expression of TIMP3 protein in tissues with AHCC was significantly correlated with tumor clinicopathological features, such as tumor size, tumor grade and stage, tumor microvessel density, and tumor blood invasion. Additionally, TIMP3 protein expression was also negatively associated with amount of AFB1-DNA adducts in tumor tissues. CONCLUSION These findings indicate that the dysregulation of TIMP3 expression is related to AHCC biological behaviors and affects tumor outcome, suggesting that TIMP3 may act as a prognostic biomarker for AHCC.

show abstract

CBX4 Expression and AFB1-Related Liver Cancer Prognosis

Cited by 3 publications

References 41 publications

The predictive potential of genetic single nucleotide polymorphisms in CBX4 for hepatocellular carcinoma survival

The predictive potential of genetic single nucleotide polymorphisms in CBX4 for hepatocellular carcinoma survival

Aflatoxin B1-DNA adducts modify the effects of post-operative adjuvant transarterial chemoembolization improving hepatocellular carcinoma prognosis

Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma

Contact Info

Product

Resources

About